Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 09, 2023 05:30 ET | Source: Opthea Limited

Opthea to Present at the Jefferies 2023 London Healthcare Conference

MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
October 30, 2023 05:30 ET | Source: Opthea Limited

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
October 27, 2023 05:30 ET | Source: Opthea Limited

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer and remains on the Board of Directors Experienced pharmaceutical executives Dr. Frederic Guerard appointed as CEO and Peter...
October 02, 2023 05:30 ET | Source: Opthea Limited

Opthea to Participate at the 2023 Euretina Congress

MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
September 07, 2023 05:30 ET | Source: Opthea Limited

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
August 28, 2023 05:30 ET | Source: Opthea Limited

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

OPT has successfully completed the placement and institutional entitlement offer components of its previously announced capital raisingAs a result of strong demand from both existing and new domestic...
July 26, 2023 06:00 ET | Source: Opthea Limited

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
July 24, 2023 06:00 ET | Source: Opthea Limited

Opthea to Present at the 2023 Ophthalmology Innovation Summit

MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
July 13, 2023 06:00 ET | Source: Opthea Limited

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseasesParticipation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD...
July 10, 2023 06:00 ET | Source: Opthea Limited

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...